Diagnostic performance of computed tomography-guided percutaneous bone biopsy in musculoskeletal oncology: A single-center cohort study

Table 2 Clinical categories and verification descriptions retained from the aggregate source record

Source clinical category	n	Reported sites (not exhaustive)	Recorded verification description
Secondary lesions: Prostate carcinoma	10	Iliac wing (4); ischial branch (1). Counts are incomplete	IHC-supported assessment and response to ADT, ADT + docetaxel, or ADT + docetaxel + ARPI. Independence of verification not established
Secondary lesions: Breast carcinoma	10	Iliac wing (2), femoral condyle, iliac body and iliac bone	IHC-supported assessment and response to CDK4/6 inhibition, trastuzumab-pertuzumab, dose-dense docetaxel, or epirubicin + cyclophosphamide, as listed in the source
Secondary lesions: Thyroid, colon, lung and urachal primaries	8	Scapula, femoral metaphysis, trochanter and L5 posterior element	IHC-supported assessment and response to cabozantinib, FOLFIRINOX, pembrolizumab or trastuzumab, as listed in the source
Osteoid osteoma, with radiofrequency ablation	4	Femoral trochanter and humeral condyle	Symptom resolution reported. Confirm actual biopsy histology and the reference-standard rule (AQ1-AQ2)
Benign lesions (enchondroma, cyst, vascular lesion)	8	Femoral condyle/head, humeral head and sternum	Surgical pathology or imaging follow-up; separate counts and dates not reported
Other primary/recurrent neoplasms: Chondrosarcoma, Ewing sarcoma, recurrent synovial sarcoma, giant cell tumor and multiple myeloma	12	Proximal femur, iliac wing (2), iliac bone, humeral head and scapula	Resection histology; myeloma assessed by IHC with response to D-VTD. Exact route counts not reported. The grouped category requires classification review
Combined discrepancy/non-neoplastic category	8	Peroneal malleolus, calcaneus, femoral condyle and iliac bone	Clinical/imaging follow-up reported; this mixed category is not equivalent to the six diagnosis-correction events
Non-diagnostic procedures	4	Iliac lesions	Final diagnosis/follow-up unavailable in the source description
Total source procedure records	64	Complete site counts pending	Verification methods are not mutually exclusive or individually enumerated

Source-data note: The three metastatic categories sum to 28 records, whereas an earlier narrative stated 59%; no replacement metastatic percentage has been asserted. Individual location counts in the source table were incomplete. These discrepancies require the original procedure-level records, not extrapolation from the older 32-case cohort. IHC: Immunohistochemistry; ADT: Androgen deprivation therapy; ARPI: Androgen receptor pathway inhibitor.